跳至主要内容
临床试验/NCT06029244
NCT06029244已完成不适用

Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE) : A Multicenter Randomized Controlled Trial

Beth Israel Deaconess Medical Center4 个研究点 分布在 2 个国家目标入组 160 人开始时间: 2024年2月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
160
试验地点
4
主要终点
Prevalence of any delirium occurrence defined as CAM ICU 7 score (>=2) during the first 7 days in ICU post-randomization or ICU discharge/death (whichever is sooner)

研究概览

简要总结

The purpose of this research is to investigate whether addition of the EyeControl-Pro platform as an adjunct to standard guideline-based intensive care unit management of critically ill patients is effective in reducing delirium incidence and severity.

详细描述

This is a prospective, binational, single-blind, multicenter, randomized control trial, conducted according to international good clinical practice (GCP) ethical and quality standards. Critically ill, mechanically ventilated patients aged >=50 years with Richmond Agitation Sedation Scale (RASS) score of -3 to +1 (at time of screening) who are anticipated to require ventilation for >=24 hours will be eligible for recruitment. The study will be conducted simultaneously at Beth Israel Deaconess Medical Center (BIDMC) Boston, USA, Assuta Ashdod Medical Center (Ashdod, Israel) and Rabin Medical Center (Petah Tikvah, Israel) with BIDMC contributing up to 50% of the total enrollment. Participants will be randomized to either a) sham device or b) active intervention arm (details described below). Legally appointed representatives, patients and caregiver teams will be administered an optional questionnaire to assess their experience with the study device at the conclusion of the study protocol. Study subjects will be administered the telephone-Montreal Cognitive Assessment (t-MoCA); total score of 22 - missing 8 points present in Montreal Cognitive Assessment (MoCA) pertaining to drawing/executive function not feasible over phone) or MoCA (if still in-hospital; assessed out of total score of 30) and Hospital Anxiety and Depression Scale (HADS) questionnaire 30 days post-randomization. Hebrew versions of these questionnaires will be used at Israeli sites.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Care Provider, Investigator, Outcomes Assessor)

盲法说明

Patients will be unblinded, or unmasked, to treatment allocation given the nature of the intervention.

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Mechanically ventilated patients aged >=50 years
  • RASS score of -3 to +1 and
  • Anticipated to require >=24 hours of mechanical ventilation

排除标准

  • Not expected to survive >=24 hours
  • Have limitations in care (Do Not Resuscitate, or comfort-focused care orders)
  • Receiving paralytic neuromuscular blocking agent (NMBA) infusion or anticipated need for NMBA use
  • Have advanced dementia or cognitive impairment including post-concussive syndrome.
  • Have severe uncorrected psychiatric disorders.
  • Have uncorrected hearing or visual impairment.
  • Acute or subacute neurological disorder hindering communication or ability to participate in CAM ICU assessments
  • Enrolled in a clinical trial which prohibits co-enrollment.
  • Incarcerated
  • Have no identified legally appointed representative (LAR)
  • Are unable to communicate in the predominant local language (English at US site and English/Hebrew/Arabic/Russian in Israel)
  • Refusal of treating clinical team.

结局指标

主要结局

Prevalence of any delirium occurrence defined as CAM ICU 7 score (>=2) during the first 7 days in ICU post-randomization or ICU discharge/death (whichever is sooner)

时间窗: Upto 7 days or liberation from ventilator whichever is sooner.

To evaluate if study subjects randomized to active EyeControl-Pro arm have a higher proportion of delirium free assessments as assessed by CAM (confusion assessment method)-ICU 7 during device usage for up to 7 days when compared with those in the sham EyeControl-Pro arm. CAM-ICU is a validated assessment tool for detection of ICU delirium.

次要结局

  • Prevalence of severe delirium assessments (defined as CAM ICU 7>=6) during the first 7 days in ICU post-randomization or ICU discharge/death (whichever is sooner)(Upto 7 days or discharge from intensive care unit (ICU) whichever is sooner)
  • Mean number of days with delirium (defined as the total number of days with at least one CAM ICU 7 positive delirium assessment within 7 days post-randomization or up to discharge from the ICU/death, whatever occurs earlier.(Upto 7 days or discharge from intensive care unit (ICU) whichever is sooner)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Somnath Bose, MD

Assistant Professor of Anesthesia, Harvard Medical School

Beth Israel Deaconess Medical Center

研究点 (4)

Loading locations...

相似试验